It is currently indicated in the adjuvant setting in early-stage hormone-receptor–positive, HER2-negative breast cancer with positive nodes stage N2 or, N1 with either grade 3 cancer or T3 tumor stage for two years. This evidence concerns the gene ERBB2 and breast carcinoma.